“We work systematically to strengthen our core business by delivering growth through the introduction of new products in existing markets and expanding products to new geographies. We have started and will continue the tedious process to increase company value by owning new products and brands. As a third step, we have been and will actively continue to source and evaluate M&A opportunities to deliver sustainable growth with the objective of building Navamedic to a leading Nordic pharmaceutical company with a footprint in North Europe and other selected countries,” says Kathrine Gamborg Andreassen, CEO of Navamedic ASA.
Stock exchange news
Navamedic ASA receives approval for conditional reimbursement for Mysimba® in Finland
Mysimba® is the first obesity treatment of its kind, combining both an oral medicin with a digital and custom-made patient Read more
Navamedic ASA: Q2 and first half 2021 financial results
“We continue to deliver rapid growth for our specialty pharma product Mysimba and consumer health products Alflorex and ThermaCare. In Read more
Navamedic ASA: Invitation to 2021 Second quarter presentation
Navamedic ASA invites you to a presentation of the 2021 second quarter results on Friday, August 13th at 08.30 CET. The Read more
Meet us at exhibitions and fairs
Unfortunately, due to Covid-19. Exhibitions are postponed or cancelled until further notice.